MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.jchf.2022.04.015

Медицинская библиотека · JACC. Heart failure · 2022

Sequential Evaluation of NT-proBNP in Heart Failure: Insights Into Clinical Outcomes and Efficacy of Vericiguat.

Armstrong Paul W, Zheng Yinggan, Troughton Richard W, Lund Lars H, Zhang Jian, Lam Carolyn S P, Westerhout Cynthia M, Blaustein Robert O, Butler Javed, Hernandez Adrian F, Roessig Lothar, O'Connor Christopher M, Voors Adrian A, Ezekowitz Justin A, VICTORIA Study Group

СтатьяПоддержка исследования: вне правительства СШАРандомизированное исследованиеКлиническое исследование III фазыПеревод в очереди

Аннотация

BACKGROUND

The effect of vericiguat on sequential N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels and influence of this relationship on clinical outcomes is unknown.

OBJECTIVES

This study assessed the relationship between changes in NT-proBNP and the primary outcome (cardiovascular death or heart failure hospitalization); evaluated the effect of vericiguat on changes in NT-proBNP; and explored the association between the efficacy of vericiguat and changes in NT-proBNP.

METHODS

NT-proBNP was measured at randomization and at 16, 32, 48, and 96 weeks in 4,805 of 5,050 patients. The association between NT-proBNP change at week 16 and the primary outcome was assessed. The relationship between changes in NT-proBNP and the primary outcome according to treatment group was assessed by using joint modeling and mediation analysis.

RESULTS

A significant and sustained decline in NT-proBNP levels was seen in both treatment groups. After week 16, NT-proBNP levels decreased more with vericiguat vs placebo (any reduction: odds ratio [OR]: 1.45 [95% CI: 1.28-1.65]; P < 0.001; ≥50% reduction: OR: 1.27 [95% CI: 1.10-1.47]; P = 0.001) and were less likely to increase (≥20% increase: OR: 0.68 [95% CI: 0.59-0.78]; P < 0.001; ≥50% increase: OR: 0.70 [95% CI: 0.59-0.82]; P < 0.001). The treatment effect related to serial NT-proBNP on the primary composite outcome was HR: 0.96 (95% CI: 0.95-0.99) at week 16, which increased to HR: 0.90 (95% CI: 0.85-0.96) at week 48; the average extent of mediation of the composite outcome related to NT-proBNP was 45%.

CONCLUSIONS

In patients with worsening HFrEF, vericiguat significantly decreased NT-proBNP levels compared with placebo. This change appeared associated with a modest relative improvement in the primary outcome of cardiovascular death or heart failure hospitalization. (Vericiguat Global Study in Subjects With Heart Failure With Reduced Ejection Fraction [VICTORIA]; NCT02861534).

Для цитирования: Armstrong Paul W, Zheng Yinggan, Troughton Richard W, Lund Lars H, Zhang Jian, Lam Carolyn S P, Westerhout Cynthia M, Blaustein Robert O, Butler Javed, Hernandez Adrian F, Roessig Lothar, O'Connor Christopher M, Voors Adrian A, Ezekowitz Justin A, VICTORIA Study Group. Sequential Evaluation of NT-proBNP in Heart Failure: Insights Into Clinical Outcomes and Efficacy of Vericiguat.. JACC. Heart failure. 2022. DOI: 10.1016/j.jchf.2022.04.015.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.